Katie Szyman has served as our Chief Executive Officer and Director since February 2025. From September 2024 to February 2025, Ms. Szyman served as Worldwide President of Advanced Patient Monitoring at BD (Becton, Dickinson and Company) which was acquired from Edwards Lifesciences. Ms. Szyman led the Critical Care business at Edwards Lifesciences for over a decade — beginning in 2014 through the acquisition by BD (Becton, Dickinson and Company) in September of 2024. While at Edwards, Ms. Szyman accelerated the revenue growth of the business by shifting to AI-driven solutions that aid clinicians in decision making and help patients return home to their families faster. Previously, Ms. Szyman spent more than 20 years at Medtronic, where she held positions with increasing levels of responsibility inside and outside the U.S., including leadership roles in corporate strategy, business development and finance, and as the worldwide president of both the Endovascular and Diabetes business units. Ms. Szyman previously served on the boards of Inari Medical (Nasdaq: NARI) starting in 2019 and Outset Medical (Nasdaq: OM) from 2021 to 2024. Ms. Szyman received a B.A. from the University of St. Thomas and an M.B.A. from Harvard Business School.

1.Give us an overview of your organisation. What are your key activities and strategic focus within the healthcare sector, particularly across the GCC and MENA region?

Masimo is a global leader in patient monitoring, dedicated to transforming healthcare through relentless innovation, empowering clinicians, and putting patients first. Our portfolio includes advanced parameters, sensors, and patient monitors, as well as connectivity, automation, and telehealth solutions. Our technologies can be found in leading hospitals around the world, including the GCC and MENA region, and are used to monitor more than 200 million patients each year.
In the GCC and broader MENA area, we work closely with Ministries of Health and Government and with numerous private hospitals and healthcare institutions, helping work toward national care improvement goals like those embodied in Saudi Arabia’s Vision 2030. We’re particularly focused on improving newborn and maternal care (for example, through the broad adoption of critical congenital heart disease screening for newborns), the use of digital health technologies, and helping doctors and hospitals provide remote patient care. We collaborate closely with Saudi Virtual Hospital, one of the most advanced virtual healthcare models in the world, helping their clinicians keep an eye on cardiac and high-acuity patients using our telehealth platform and next-generation wearable monitoring devices. We believe it’s not only possible to facilitate better care through continuous monitoring from curb to curb inside the hospital, but by making it possible for clinicians in both private hospitals and public health programs to keep an eye on patients at home and throughout their communities, at scale.
In summary, Masimo does more than just provide the technology that supports hospitals and doctors: We engage with healthcare leaders throughout the GCC and MENA region to develop solutions and scalable models of care together.

2. What emerging trends and critical challenges do you believe are most significantly influencing the industry's trajectory in this region?

Healthcare in the GCC and wider MENA area is at a critical juncture, driven by ambitious transformation objectives and very real system-level issues. One of the most notable changes is the transition to value-based and outcomes-driven care. Governments and healthcare authorities are shifting away from volume-based models and towards accountability for quality, safety, and efficiency. This is driving demand for technologies that produce reliable clinical data, support clinicians in promoting early intervention, and demonstrate measurable impact through high-quality clinical evidence. Masimo’s track record of innovating reliable, clinically proven, insightful technologies makes us an ideal partner for healthcare providers throughout the region. At the same time, virtual care and remote monitoring are quickly expanding, especially as demographic and disease-burden challenges (like the rising incidence of cardiovascular disease and diabetes) grow. Population expansion, geographic dispersion, and personnel constraints are driving significant investment in national virtual hospital models, home care, and decentralized services. However, the difficulty is to ensure interoperability, clinical trust, and long-term adoption, rather than simply introducing digital technologies. Here again, Masimo—with our expertise in remote supplemental monitoring, secure network connectivity, and data automation—is well positioned to collaborate with institutions and communities to answer these needs and improve outcomes region-wide.

3. What is your strategic outlook for the healthcare sector over the next decade? How do you anticipate the industry will evolve?

Masimo’s goal is to expand our global leadership in monitoring, and continue to make a difference in patients’ lives, and to do so, it’s critical that we expand our impact in new patient pathways, in an area we see the healthcare sector evolving: the growth of continuous monitoring throughout the hospital. Innovations like ours have demonstrated that hospitals provide more proactive, more effective care when they expand how, when, and where they monitor their patients—beyond traditional areas like the OR and ICU and into step-down units, discharge units, the general floor, and transitional areas like ED waiting rooms. Studies have shown that not only does this kind of curb-to-curb monitoring improve patient outcomes, preventing the kinds of escalations and re-escalations of care that could have been prevented if worsening physiological status were caught sooner, but it also saves institutions money. Frankly, continuous, or surveillance monitoring, is a win-win for hospitals, and we believe Masimo is uniquely positioned—given our track record of innovation in advanced monitoring, wearable devices, and automation solutions—to partner with leading institutions around the world to foster widespread adoption.

4. What role does innovation play in your organisation's strategic framework? Please elaborate on your R&D initiatives and share insights into any significant projects currently in development or recently launched.

Innovation is key to Masimo’s heritage and our future: our company was founded to address an unsolvable problem—the inability of legacy pulse oximetry technology to accurately measure neonatal oxygen saturation in the common but challenging conditions of motion and low perfusion—and ever since, our innovations have been empowering clinicians to transform the quality and efficacy of the care they can provide.
As we look ahead, we’re focusing on a range of monitoring modalities that take advantage of our expertise in AI-driven smart algorithms to enable better, more effective, more personalized monitoring across a range of physiological parameters—from Pulse CO-Oximetry and brain monitoring to hemodynamics, capnography, and beyond. Coupled with these advanced smart monitoring technologies are a host of next-generation bedside and wearable devices that facilitate tetherless monitoring, seamless data translation and automation, and ever-more sophisticated remote and supplemental patient monitoring and management, including telehealth solutions. Together, these innovations will enable the true curb-to-curb monitoring that we believe is key to overall improvements in patient care and health around the world.

5. How is your organisation integrating sustainability principles into your healthcare operations? If any, what specific initiatives have you implemented to minimise environmental impact and advance sustainable healthcare practices?

Masimo is committed to reducing our environmental impact while delivering innovative, cost-effective care solutions for our customers around the world. From the design of our sensors to our end-of-life recycling program, we are steadfastly focused on how we can make our products and processes as sustainable as possible. We’re particularly proud of our zero waste-to-landfill recycling program, which ensures that hundreds of thousands of pounds of used sensors are collected and processed by e-waste facilities to recover available recyclable materials. Our RD line of sensors, used by an ever-growing number of hospitals and institutions, offer significant sustainability benefits, such as using significantly less material and packaging, without sacrificing performance and actually offering improved accuracy. These are just a couple of our numerous sustainability initiatives. By conserving energy and reducing material use and waste in our product designs, packaging, and distribution, as well as minimizing our carbon footprint, we hope to promote the health of our environment and encourage our partners throughout the GCC and MENA region to work with us to do the same.

6.What innovations or solutions is your organisation planning to present at WHX Dubai 2026? Are there any particular offerings you are especially excited to showcase and experience yourself?

At WHX Dubai 2026, we are looking forward to showcasing a full array of our advanced monitoring technologies, next-generation devices—from wearables to handhelds to bedside monitors—and automation and connectivity solutions. All of these solutions, and the future innovations we’re hard at work on, are designed to help providers bring about the true curb-to-curb continuous patient monitoring, alongside seamless virtual care, that we believe represents the future of connected care in the GCC and MENA region and beyond. We plan to showcase our breakthrough SET® pulse oximetry and rainbow® Pulse CO-Oximetry parameters, which allow accurate, reliable noninvasive and continuous monitoring in challenging conditions like motion and low perfusion, across all skin tones, and of blood constituents that previously could only be measured invasively, like total hemoglobin (SpHb®). In additional we’ll feature modalities such as LiDCO® hemodynamic monitoring, SedLine® and O3® brain monitoring, and NomoLine® capnography, that offer the advanced, rich data that support informed care decisions. Among other devices and systems solutions we’ll be showcasing, we plan to demonstrate key components of our Hospital Automation™ platform, such as the Root® monitoring hub, the versatile, patient-worn Radius VSM® vital signs monitor, and Patient SafetyNet™, our hospital-based supplemental monitoring and clinician notification platform. And, to illustrate the power and value of our telehealth capabilities, we’ll be exhibiting Masimo SafetyNet® and how it integrates with at-home wearables like the Masimo W1® medical watch and Radius PPG® tetherless pulse oximetry.

7. Is there anything else you would like to add?

We’re truly excited about the future of healthcare in the GCC and greater MENA region and how we can partner with its leaders, health ministries, institutions, doctors, nurses, and researchers to improve the health and lives of its citizens. As impressive as our track record of innovation and excellence is, there are still so many opportunities for us to help clinicians transform patient care in so many scenarios, so many settings, so many ways. We’re steadfastly and passionately focused on how we can empower clinicians with the next generation of medical monitoring technologies. Even after 35 years of advancing care, we’re just beginning.